PMA device
Infuse Bone Graft
Medtronic, Inc. · Bone Grafting Material, Dental, With Biologic Component (NPZ, Class III) · First FDA decision Mar 9, 2007, newest Aug 26, 2026Gum diseaseTooth loss and dental implants
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
13
PMA pathway
Device trials
57
Naming "Infuse"
MAUDE reports
4,412
Brand "Infuse", since 2015
PubMed studies
1,498
Mentioning "Infuse"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Infuse Bone Graft
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 13 decisions filed under this name.
- INFUSE BONE GRAFTPMA supplement
P050053-S066 · Decided Aug 26, 2026 · 530 days after receipt · Normal 180 Day Track
Device type: Bone grafting material, dental, with biologic component (NPZ) · Dentistry & Oral Surgery
5 more FDA decisions with a free account
Older decisions: P050053-S024, P050053-S017, P050053-S015, P050053-S008, P050053-S005, P050053-S001, P050053
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Infuse", any status and sponsor, newest update first.
Johnson & Johnson Vision Care, Inc.Not on our public-company list
NCT07076160 · 74 participants · Start Jul 24, 2025 · Primary completion Sep 20, 2025
Device: INFUSE® One Day Multifocal; ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens · For: Visual Acuity; Presbyopia
Sites: Jacksonville, Florida; Longwood, Florida; Maitland, Florida · 7 sites in all
56 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Infuse", and for the whole product code for context.
This brand
4,412 reports: 52 malfunction, 4,351 injury, 6 death
Whole product code NPZ
34 reports: 0 malfunction, 33 injury, 0 death
Newest reports for this brand
- INFUSE Bone GraftInjury
MEDTRONIC SOFAMOR DANEK USA, INC.
3003120897-2026-01756 · Received Oct 23, 2026 · Event dated Jul 17, 2026
Device type: Filler, Recombinant Human Bone Morphogenetic Protein, Collagen Scaffold With Metal Prosthesis, Osteoinduction (NEK)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Bone Fracture(s); Back pain
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Medtronic Sofamor Danek USA Inc
Z-0440-2019 · Started Sep 27, 2018
Reason given: The Extra Small INFUSE Bone Graft kit from lot M111806AAA, may contain two absorbable collagen sponges (ACS), but should only contain one ACS.
Cause as FDA categorized it: Error in labeling · Device type: Filler, Recombinant Human Bone Morphogenetic Protein, Collagen Scaffold With Metal Prosthesis, Osteoinduction (NEK)
Published research
The most relevant PubMed records for "Infuse"[tiab]. The summary above synthesizes these.
- Iatrogenic kindness.
Jesudason E · J Med Ethics · 2025
- How we infuse blinatumomab.
Oranges K, Windawi S, Powell S, et al. · Pediatr Blood Cancer · 2020
- Translating Trauma-Informed Principles into Social Work Practice.
Levenson J · Soc Work · 2020
- Infuse-as-you-go convective delivery to enhance coverage of elongated brain targets: technical note.
Sudhakar V, Naidoo J, Samaranch L, et al. · J Neurosurg · 2020
- To Infuse or Ingest in Human Laboratory Alcohol Research.
Cyders MA, Plawecki MH, Corbin W, et al. · Alcohol Clin Exp Res · 2020Research Support, N.I.H., Extramural, Review
- Microdialysis in rodents.
Zapata A, Chefer VI, Shippenberg TS · Curr Protoc Neurosci · 2009
- Microdialysis in rodents.
Thompson AC, Shippenberg TS · Curr Protoc Neurosci · 2001
- Genomics in nursing education.
Seibert D · J Am Assoc Nurse Pract · 2020
- Response to: Should we infuse more fluids in liver resection?
Coeckelenbergh S, Van der Linden P, Joosten A · Eur J Anaesthesiol · 2022Letter, Comment
- Intravenous fluids: balancing solutions.
Hoorn EJ · J Nephrol · 2017Review
- 5-Fluorouracil induced extravasation injury.
Reddy SS, Somayaji S, Krishna Murthy M, et al. · Indian J Cancer · 2020Case Reports
- How to Infuse Joy in Your Practice: Our Journey to Sustainable Well-Being.
Stonnington CM, Jones K, Leighton JA · Am J Gastroenterol · 2022
Other devices of this type
Also filed under product code NPZ.
- Gem 21S Growth Factor Enhanced MatrixLynch Biologics, LLC · PMA 2011
- GEM21S Growth Factor Enhanced MatrixLynch Biologics, LLC · PMA 2020
- Gem 21S (Growth Enhanced Matrix)Lynch Biologics, LLC · PMA 2008
- Pepgen P-15, Pepgen P-15 Flow & Pepgen P-15 PuttyCeramed Corp. · PMA 2007
- Pepgen P-15 Dental Bone Grafting Material with Biologic ComponentCeramed Corp. · PMA 2006
- GEM215 Growth Factor Enhanced MatrixLynch Biologics, LLC · PMA 2020
- Gem 21SGROWTH Factor Enhanced MatrixLynch Biologics, LLC · PMA 2011
- Pepgen 15Ceramed Corp. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.